Nu Eyne, a company specializing in non-pharmacological neurostimulation-based treatment devices, announced on the 2nd that it signed a contract with Nurturing Med, a local Chinese medical platform company, to operate an ADHD and developmental disorder treatment program and held an official signing ceremony at its headquarters in Seoul.
Under this agreement, Nurturing Med will fully introduce Nuain’s ADHD treatment device, ‘Smile’, into its program through special approval in Hainan, China, starting in June. ‘Smile’ is a program that complements the limitations of drug treatment and aims to improve non-pharmacological concentration and cognitive stimulation, and is gaining attention as an alternative treatment for ADHD/ASD for children and adolescents in China.
It was reported that Nurturing Med officials attended the signing ceremony and visited Nuain’s production facility to directly check out its manufacturing capabilities and quality management system. The two sides also discussed ways to expand their business in the future based on their initial partnership.
Newain expects to generate approximately KRW 1 billion in sales through this contract in 2025, explaining that this is very significant as it is their first official entry into the Chinese market. In addition, they stated that based on the success of the local program, they will pursue NMPA (China National Medical Products Administration) approval for expansion throughout China within the next two years, and aim to achieve approximately USD 10 million in sales within four years.
- See more related articles
You must be logged in to post a comment.